Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
48.9M
-
Number of holders
-
159
-
Total 13F shares, excl. options
-
21.2M
-
Shares change
-
+2.42M
-
Total reported value, excl. options
-
$813M
-
Value change
-
+$86.6M
-
Put/Call ratio
-
0.98
-
Number of buys
-
85
-
Number of sells
-
-62
-
Price
-
$38.30
Significant Holders of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) as of Q2 2022
217 filings reported holding AXSM - Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2022.
Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) has 159 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.2M shares
of 48.9M outstanding shares and own 43.37% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (2.8M shares), BlackRock Inc. (2.23M shares), RTW INVESTMENTS, LP (1.62M shares), PFM Health Sciences, LP (1.36M shares), Fairmount Funds Management LLC (943K shares), STATE STREET CORP (853K shares), Bellevue Group AG (817K shares), ALETHEA CAPITAL MANAGEMENT, LLC (790K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (784K shares), and Nuveen Asset Management, LLC (771K shares).
This table shows the top 159 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.